Duotide Inhalation Capsule 25 mcg+62.5 mcg combines Vilanterol Trifenatate 25 mcg, a long-acting beta-2 adrenergic agonist (LABA), and Umeclidinium Bromide 62.5 mcg, a long-acting muscarinic antagonist (LAMA), in a single inhalation therapy. This dual-action formulation is designed for the maintenance treatment of chronic obstructive pulmonary disease (COPD), providing enhanced bronchodilation and improved symptom control.

COPD is a progressive respiratory disease characterized by airflow limitation, chronic inflammation, and recurrent exacerbations, resulting in shortness of breath, wheezing, chronic cough, and reduced exercise capacity. The combination of Vilanterol and Umeclidinium targets different pathways of airway constriction, offering synergistic bronchodilation. This improves lung function, reduces breathlessness, and enhances quality of life for patients living with COPD.

Duotide Inhalation Capsules are designed for direct lung delivery via a dry powder inhaler (DPI), ensuring rapid onset of action, sustained effects, and once-daily dosing convenience for better patient adherence. This makes it particularly suitable for patients with moderate to severe COPD who require long-term, effective symptom management.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Duotide Inhalation Capsule 25 mcg+62.5 mcg is indicated for:

• Maintenance treatment of moderate to severe COPD

• Reduction of dyspnea (shortness of breath) in COPD patients

• Improvement of lung function, exercise tolerance, and daily activity

• Prevention of COPD exacerbations when used as part of a long-term management plan

Key Benefits

• Provides dual bronchodilation through LABA and LAMA combination

• Enhances airflow and reduces airway resistance

• Relieves symptoms such as breathlessness, wheezing, and chest tightness

• Convenient once-daily dosing improves treatment adherence

• Direct inhalation ensures rapid onset and minimizes systemic side effects

Mechanism of Action

• Vilanterol Trifenatate (25 mcg): A long-acting beta-2 adrenergic receptor agonist that relaxes airway smooth muscles by stimulating beta-2 receptors, leading to bronchodilation and improved airflow.

• Umeclidinium Bromide (62.5 mcg): A long-acting muscarinic antagonist that blocks acetylcholine at muscarinic receptors, preventing bronchoconstriction and reducing mucus secretion.

The complementary actions of these two agents produce synergistic bronchodilation, targeting separate pathways to maximize airway opening, reduce hyperinflation, and improve respiratory function in COPD patients.

Dosage and Administration

• One inhalation capsule daily using a compatible dry powder inhaler (DPI).

• Do not swallow the capsule; it must be inhaled using the prescribed inhaler device.

• Take at the same time every day for consistent therapeutic effect.

• Do not exceed the recommended dose.

Precautions

• Not suitable for acute bronchospasm; this therapy is for maintenance treatment only.

• Use with caution in patients with cardiovascular disease, arrhythmias, glaucoma, or urinary retention.

• Inform your physician about all medications being taken to avoid potential drug interactions.

• Seek medical attention if experiencing severe palpitations, chest pain, or difficulty breathing.

• Not recommended for children or adolescents under 18 years unless prescribed.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Duotide Inhalation Capsule 25 mcg+62.5 mcg is generally well tolerated. Side effects may include:

• Dry mouth

• Headache

• Cough or throat irritation

• Mild palpitations or tremors

• Rarely, urinary retention or blurred vision

Most side effects are mild and transient, resolving with continued use. Dose adjustments may reduce adverse effects.

Storage

Store below 30°C in a cool, dry place, away from moisture and direct sunlight. Keep capsules out of reach of children.